Skip to Main Content

Paper Details

Development and Validation of a Scoring System to Predict Outcomes of Vedolizumab Treatment in Patients With Crohn's Disease.
Gastroenterology
90
2018
C-reactive protein, CD, Crohn's Disease, Crohn's disease, MH, Patients, Vedolizumab, albumin, fistulizing disease, inflammatory bowel diseases, participants, patients, tumor necrosis factor, vedolizumab
Author NameAffiliation
Parambir S DulaiUniversity of California-San Diego
Brigid S BolandUniversity of California-San Diego
Brigid S BolandUniversity of California-San Diego
Siddharth SinghUniversity of California-San Diego
Khadija ChaudreyMayo Clinic
Eugenia ShmidtIcahn School of Medicine at Mount Sinai
Diana WhiteheadDartmouth-Hitchcock Medical Center
Robert HirtenNorth Shore University Hospital
Farhad PeeraniIcahn School of Medicine at Mount Sinai, New York University of Alberta
Neeraj NarulaIcahn School of Medicine at Mount Sinai, New York McMaster University Medical Centre
Arun SwaminathLenox Hill Hospital
Dana J LukinMontefiore Medical Center
David HudesmanNew York University (NYU)
John T ChangUniversity of California-San Diego
John T ChangUniversity of California-San Diego
Vipul JairathUniversity of Western Ontario
Corey A SiegelDartmouth-Hitchcock Medical Center
Edward V LoftusMayo Clinic
Sunanda V KaneMayo Clinic
Bruce E SandsIcahn School of Medicine at Mount Sinai
Jean-Frederic ColombelIcahn School of Medicine at Mount Sinai
William J SandbornUniversity of California-San Diego
  • 1 - 22

Datasets

Release 1.2